IL276286B2 - FC variants with improved binding to FCRN and extended half-life - Google Patents

FC variants with improved binding to FCRN and extended half-life

Info

Publication number
IL276286B2
IL276286B2 IL276286A IL27628620A IL276286B2 IL 276286 B2 IL276286 B2 IL 276286B2 IL 276286 A IL276286 A IL 276286A IL 27628620 A IL27628620 A IL 27628620A IL 276286 B2 IL276286 B2 IL 276286B2
Authority
IL
Israel
Prior art keywords
amino acid
acid position
tyrosine
binding polypeptide
domain
Prior art date
Application number
IL276286A
Other languages
English (en)
Hebrew (he)
Other versions
IL276286B1 (en
IL276286A (en
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65520379&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL276286(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of IL276286A publication Critical patent/IL276286A/en
Publication of IL276286B1 publication Critical patent/IL276286B1/en
Publication of IL276286B2 publication Critical patent/IL276286B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL276286A 2018-01-26 2019-01-25 FC variants with improved binding to FCRN and extended half-life IL276286B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862622468P 2018-01-26 2018-01-26
PCT/US2019/015204 WO2019147973A1 (en) 2018-01-26 2019-01-25 Fc variants with enhanced binding to fcrn and prolonged half-life

Publications (3)

Publication Number Publication Date
IL276286A IL276286A (en) 2020-09-30
IL276286B1 IL276286B1 (en) 2025-03-01
IL276286B2 true IL276286B2 (en) 2025-07-01

Family

ID=65520379

Family Applications (2)

Application Number Title Priority Date Filing Date
IL276286A IL276286B2 (en) 2018-01-26 2019-01-25 FC variants with improved binding to FCRN and extended half-life
IL318916A IL318916A (en) 2018-01-26 2019-01-25 FC variants with improved binding to FCRN and extended half-life

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL318916A IL318916A (en) 2018-01-26 2019-01-25 FC variants with improved binding to FCRN and extended half-life

Country Status (16)

Country Link
US (1) US20190263934A1 (https=)
EP (1) EP3743441A1 (https=)
JP (3) JP7399880B2 (https=)
KR (2) KR20250008975A (https=)
CN (2) CN111788221B (https=)
AU (2) AU2019212638B2 (https=)
BR (1) BR112020015006A2 (https=)
CA (1) CA3089602A1 (https=)
CO (1) CO2020010269A2 (https=)
IL (2) IL276286B2 (https=)
MX (2) MX2020007882A (https=)
MY (1) MY203898A (https=)
PH (1) PH12020551134A1 (https=)
SG (1) SG11202006905YA (https=)
TW (1) TW201940512A (https=)
WO (1) WO2019147973A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL276286B2 (en) * 2018-01-26 2025-07-01 Genzyme Corp FC variants with improved binding to FCRN and extended half-life
WO2021016571A2 (en) * 2019-07-25 2021-01-28 Genzyme Corporation Methods of treating antibody-mediated disorders with fcrn antagonists
CA3156803A1 (en) 2019-10-03 2021-04-08 Atyr Pharma, Inc. Compositions and methods comprising anti-nrp2 antibodies
CN120590527A (zh) * 2020-05-11 2025-09-05 因外泰克斯公司 用于增加治疗剂在犬中的半衰期的组合物和使用方法
KR20230093483A (ko) * 2020-10-29 2023-06-27 포르미콘 아게 Ace2 융합 단백질 및 이의 용도
EP4347640A1 (en) 2021-05-27 2024-04-10 Sanofi Fc variant with enhanced affinity to fc receptors and improved thermal stability
AU2022329459A1 (en) 2021-08-20 2024-02-29 Intervet International B.V. Antibodies and igg fusion proteins with an extended half-life
WO2023064841A1 (en) * 2021-10-13 2023-04-20 The Wistar Institute Of Anatomy And Biology Antibodies for use against sars-cov-2
KR20250017240A (ko) 2022-05-27 2025-02-04 사노피 FC-조작을 갖는 NKp46 및 BCMA 변이체에 결합하는 자연 살해(NK) 세포 관여자
CN116162171B (zh) * 2022-10-13 2025-06-03 深圳市百士通科技开发有限公司 抗体突变方法在治疗性抗体药物中的应用
WO2024089609A1 (en) 2022-10-25 2024-05-02 Ablynx N.V. Glycoengineered fc variant polypeptides with enhanced effector function
EP4630455A1 (en) 2022-12-05 2025-10-15 Sanofi Transferrin receptor binding proteins
TW202535925A (zh) 2023-10-25 2025-09-16 比利時商艾伯霖克斯公司 具有增強的Ｆｃ受體結合之Ｆｃ結構域變體
WO2025101094A1 (en) * 2023-11-08 2025-05-15 Ооо «Geropharm» Fc fragment polypeptide for producing therapeutically active fusion polypeptides and conjugates
WO2025149633A1 (en) 2024-01-12 2025-07-17 Laigo Bio B.V. Bispecific antigen binding proteins
WO2026022712A1 (en) 2024-07-23 2026-01-29 Sanofi Cereblon ligase modulator and bcma nk cell engager combination therapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013047748A1 (ja) * 2011-09-30 2013-04-04 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0627932B1 (en) 1992-11-04 2002-05-08 City Of Hope Antibody construct
BR9606706A (pt) 1995-10-16 1999-04-06 Unilever Nv Análogo de fragmento de anticorpo biespecífico ou bivalente uso processo para produzir o mesmo
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
PL209392B1 (pl) * 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
CA2410551A1 (en) 2000-06-30 2002-01-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw (Vib) Heterodimeric fusion proteins
AU2004266159A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
AU2005285347A1 (en) * 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
AU2005304624B2 (en) * 2004-11-12 2010-10-07 Xencor, Inc. Fc variants with altered binding to FcRn
WO2006130834A2 (en) * 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
WO2010068722A1 (en) * 2008-12-12 2010-06-17 Medimmune, Llc Crystals and structure of a human igg fc variant with enhanced fcrn binding
DK2516468T3 (en) * 2009-12-23 2016-05-23 Synimmune Gmbh ANTI-FLT3 ANTIBODIES AND METHODS FOR USING THESE
WO2011089211A1 (en) * 2010-01-22 2011-07-28 Synimmune Gmbh Anti-cd133 antibodies and methods of using the same
TWI743461B (zh) 2011-03-28 2021-10-21 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
GB201112429D0 (en) * 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
US20140294812A1 (en) * 2013-03-15 2014-10-02 Xencor, Inc. Fc variants that improve fcrn binding and/or increase antibody half-life
WO2014177459A2 (en) * 2013-04-29 2014-11-06 F. Hoffmann-La Roche Ag Fc-receptor binding modified asymmetric antibodies and methods of use
DK3215528T3 (da) * 2014-11-06 2019-10-07 Hoffmann La Roche Fc-regionvarianter med modificeret FcRn-binding og anvendelsesfremgangsmåder
JP6787888B2 (ja) * 2014-11-10 2020-11-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗ｉｌ−１ベータ抗体及び使用方法
HRP20260151T1 (hr) * 2016-08-02 2026-03-27 Visterra, Inc. Modificirani polipeptidi i njihova uporaba
IL276286B2 (en) * 2018-01-26 2025-07-01 Genzyme Corp FC variants with improved binding to FCRN and extended half-life

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013047748A1 (ja) * 2011-09-30 2013-04-04 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子

Also Published As

Publication number Publication date
MY203898A (en) 2024-07-23
RU2020128177A (ru) 2022-02-28
TW201940512A (zh) 2019-10-16
IL276286B1 (en) 2025-03-01
CA3089602A1 (en) 2019-08-01
AU2019212638B2 (en) 2025-04-03
KR102748986B1 (ko) 2025-01-02
AU2019212638A1 (en) 2020-09-17
IL318916A (en) 2025-04-01
EP3743441A1 (en) 2020-12-02
KR20200115568A (ko) 2020-10-07
CN119350481A (zh) 2025-01-24
BR112020015006A2 (pt) 2020-12-29
CN111788221B (zh) 2026-02-13
CO2020010269A2 (es) 2020-12-10
KR20250008975A (ko) 2025-01-16
MX2025009543A (es) 2025-09-02
JP7399880B2 (ja) 2023-12-18
MX2020007882A (es) 2020-12-03
CN111788221A (zh) 2020-10-16
WO2019147973A1 (en) 2019-08-01
PH12020551134A1 (en) 2021-05-31
AU2025204826A1 (en) 2025-07-17
US20190263934A1 (en) 2019-08-29
JP2026021377A (ja) 2026-02-10
JP2021511830A (ja) 2021-05-13
JP2024026255A (ja) 2024-02-28
NZ767453A (en) 2025-03-28
SG11202006905YA (en) 2020-08-28
IL276286A (en) 2020-09-30

Similar Documents

Publication Publication Date Title
IL276286B2 (en) FC variants with improved binding to FCRN and extended half-life
JP2024026255A5 (https=)
JP2021511830A5 (https=)
CN110382529B (zh) 工程化的异源二聚体蛋白质
CN110520445B (zh) 抗pd-l1/抗pd-1天然抗体结构样异源二聚体形式双特异抗体及其制备
CN111971301B (zh) 抗ms4a4a抗体及其使用方法
JP2012515556A5 (https=)
TWI585104B (zh) 基於vl和vhh可變區衍生物的高親和力抗聚集抗體
KR102247704B1 (ko) 항 pd-1/항 her2 천연항체 구조 형태의 헤테로다이머 계의 이중특이성 항체 및 그 제조방법
CA2502904A1 (en) Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
TR201808458T4 (tr) FC-reseptör bazlı afinite kromatografisi.
CN113227134A (zh) 抗体的Fc区变体
WO2015033223A2 (en) Readily isolated bispecific binding molecules with native format having mutated constant regions
CN106459191B (zh) 选择具有修饰的FcRn相互作用的抗体的方法
EP2773660A2 (en) Chimeric human-camel antigens and their use
KR20180034500A (ko) 친화성 크로마토그래피에서의 숙주 세포 단백질 감소 방법
US20250266122A1 (en) Multi-domain proteins with increased native state colloidal stability
EP3615678A1 (en) Antibody selection method
TW201716442A (zh) 抗EphA4抗體
TW202233694A (zh) 雙特異性抗體
CN111491951A (zh) 通过疏水相互作用色谱法耗尽轻链错配的抗体变体
CN112513074A (zh) 生产两种或更多种不同抗体的受控混合物的方法
WO2022117065A1 (zh) 多特异性抗原结合蛋白
CN112703204B (zh) 针对可溶性bcma的抗体
KR20150134319A (ko) 인간화 항 hmgb1 항체 또는 그의 항원 결합성 단편